ImmunityBio (NASDAQ:IBRX) Receives Buy Rating from D. Boral Capital

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $23.00 price target on the stock. D. Boral Capital’s target price would suggest a potential upside of 235.28% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Jefferies Financial Group raised their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. HC Wainwright raised their price objective on shares of ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. The Goldman Sachs Group reiterated a “buy” rating on shares of ImmunityBio in a research note on Monday, February 23rd. Finally, BTIG Research initiated coverage on shares of ImmunityBio in a research note on Thursday, March 12th. They issued a “buy” rating and a $13.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $14.40.

ImmunityBio Stock Performance

IBRX stock opened at $6.86 on Wednesday. ImmunityBio has a one year low of $1.83 and a one year high of $12.43. The stock has a market capitalization of $7.05 billion, a PE ratio of -18.05 and a beta of 0.13. The company has a fifty day moving average of $7.78 and a 200-day moving average of $4.46.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Monday, February 23rd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $38.29 million during the quarter. Equities analysts forecast that ImmunityBio will post -0.92 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Christobel Selecky sold 25,000 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $10.00, for a total value of $250,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Barry J. Simon sold 75,000 shares of ImmunityBio stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $12.01, for a total transaction of $900,750.00. Following the transaction, the director owned 2,850,821 shares of the company’s stock, valued at approximately $34,238,360.21. The trade was a 2.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 501,967 shares of company stock valued at $4,466,412 in the last quarter. Company insiders own 69.48% of the company’s stock.

Hedge Funds Weigh In On ImmunityBio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IBRX. Armistice Capital LLC acquired a new position in ImmunityBio during the second quarter worth about $20,497,000. Heights Capital Management Inc. acquired a new position in ImmunityBio during the third quarter worth about $16,152,000. Vanguard Group Inc. raised its position in ImmunityBio by 26.8% during the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock worth $68,032,000 after acquiring an additional 5,837,898 shares during the last quarter. State Street Corp raised its position in ImmunityBio by 45.4% during the fourth quarter. State Street Corp now owns 16,455,703 shares of the company’s stock worth $32,582,000 after acquiring an additional 5,139,890 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in ImmunityBio by 439.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock worth $12,182,000 after acquiring an additional 5,012,001 shares during the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio says it submitted a comprehensive response to the FDA’s OPDP concerns, confirmed the TV ad was never aired, addressed the podcast issues and pledged tighter advertising oversight — a compliance step that could limit further regulatory damage. ImmunityBio Addresses FDA Correspondence
• Positive Sentiment: Some market coverage noted an immediate, modest rebound after the company’s compliance response (reports of a ~3% intraday uptick), suggesting short-term relief for investors who view the company’s corrective actions as credible. ImmunityBio Stock Gains 3%
• Positive Sentiment: At least one sell-side commentary (BTIG) remains constructive on IBRX despite the OPDP action, which may temper longer-term selling if commercial momentum and clinical data continue to support the story. ImmunityBio Faces FDA Warning, BTIG Stays Positive
• Neutral Sentiment: Coverage highlights the company’s stated compliance fixes alongside ongoing sales/expansion efforts; investors will watch whether operational performance offsets reputational/regulatory risk. IBRX Responds to FDA Warning
• Neutral Sentiment: Some analysts and outlets speculate shorter-term technical snapshots (e.g., whether the stock will “snap” a brief losing streak) and focus on upcoming data links for Anktiva; these are market-moving only if new data or guidance appears. IBRX Stock Set to Snap 2 Days of Losses?
• Negative Sentiment: Regulatory action sparked a major market reaction: headlines noted a sharp (~21%) prior share plunge after the FDA flagged potentially misleading efficacy claims for Anktiva — an event that materially increases reputational and litigation risk for the company. IBRX Shareholder Update – Hagens Berman
• Negative Sentiment: Multiple law firms have filed securities class actions or are soliciting lead-plaintiff applications alleging misleading statements about Anktiva; dozens of counsel notices cite a May 26, 2026 deadline to seek lead-plaintiff status — this concentrated litigation activity is a clear near-term negative for valuation and shareholder sentiment. ImmunityBio Securities Fraud Class Action – Kahn Swick

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.